

Sabina Antonela Antoniu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8965472/sabina-antonela-antoniou-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

117
papers

721
citations

13
h-index

20
g-index

126
ext. papers

823
ext. citations

5.3
avg, IF

4.98
L-index

#	Paper	IF	Citations
117	Romanian Guidelines for the Diagnosis and Treatment of GERD-induced Respiratory Manifestations.. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2022 , 31, 119-142	1.4	1
116	Determinants of the Hesitancy toward COVID-19 Vaccination in Eastern European Countries and the Relationship with Health and Vaccine Literacy: A Literature Review. <i>Vaccines</i> , 2022 , 10, 672	5.3	3
115	Inhaled interferons beta and SARS-COV2 infection: a preliminary therapeutic perspective. <i>Expert Review of Respiratory Medicine</i> , 2021 , 1-5	3.8	0
114	Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 835-847	4	0
113	Frailty, a Dimension of Impaired Functional Status in Advanced COPD: Utility and Clinical Applicability. <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	1
112	Treatment of fibrous dysplasia: focus on denosumab.. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-9	5.4	0
111	Pharmacotherapy options in pulmonary alveolar proteinosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 1359-1366	4	2
110	Evaluating revefenacin as a therapeutic option for chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 997-1004	4	1
109	Pulmonologists Adherence to the Chronic Obstructive Pulmonary Disease GOLD Guidelines: A Goal to Improve. <i>Medicina (Lithuania)</i> , 2020 , 56,	3.1	3
108	Extra-respiratory symptoms in patients hospitalized for a COPD exacerbation: Prevalence, clinical burden and their impact on functional status. <i>Clinical Respiratory Journal</i> , 2019 , 13, 735-740	1.7	2
107	Belimumab and antipneumococcal vaccination in patients with systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 175-177	5.1	2
106	Investigational inhaled therapies for non-CF bronchiectasis. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 139-146	5.9	4
105	Benralizumab as a potential treatment of asthma. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 895-909	9.4	3
104	Lebrikizumab for the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 1239-49	5.9	5
103	Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 165-7	3.5	4
102	Impact of fatigue in patients with chronic obstructive pulmonary disease: results from an exploratory study. <i>Therapeutic Advances in Respiratory Disease</i> , 2016 , 10, 26-33	4.9	20
101	Palliative care outcome measures in COPD patients: a conceptual review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016 , 16, 267-74	2.2	3

100	Predictors of Mortality in Patients with COPD and Chronic Respiratory Failure: The Quality-of-Life Evaluation and Survival Study (QuESS): A Three-Year Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016 , 13, 130-8	2	18
99	Nivolumab for advanced non-small cell lung cancer: an immunologically-mediated tumor checkout. <i>Annals of Translational Medicine</i> , 2016 , 4, 201	3.2	4
98	Efficacy of indacaterol as a single therapy versus salmeterol/fluticasone therapy in patients with milder chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1539-41	4	
97	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (August-October 2014). <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 321-328	1.1	
96	Fresh from the designation pipeline: orphan drugs designated in the European Union (November-December 2014). <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 719-725	1.1	1
95	Measuring fatigue as a symptom in COPD: From descriptors and questionnaires to the importance of the problem. <i>Chronic Respiratory Disease</i> , 2015 , 12, 179-88	3	22
94	Novel inhaled combined antibiotic formulations in the treatment of <i>Pseudomonas aeruginosa</i> airways infections in cystic fibrosis. <i>Expert Review of Anti-Infective Therapy</i> , 2015 , 13, 897-905	5.5	14
93	Targeting 5-lipoxygenase-activating protein in asthma and chronic obstructive pulmonary disease. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 1285-92	6.4	12
92	Asthma and pregnancy: therapeutic challenges. <i>Archives of Gynecology and Obstetrics</i> , 2014 , 290, 621-7	2.5	1
91	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (December 2013-February 2014). <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 635-641	1.1	
90	Fresh from the designation pipeline: orphan drugs recently designated in the EU (June-July 2014). <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 1309-1313	1.1	
89	Immune therapies for malignant mesothelioma. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 965-73	3.5	1
88	Efficacy of budesonide in collagenous colitis Evaluation of: Miehlke S, Madisch A, Kupcinskas L, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. <i>Gastroenterology</i> 2014;146(5):1222-1230 e1222. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2277-9	4	2
87	Combined long-acting bronchodilator single therapy for COPD. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 139-42	4	5
86	Health status during hospitalisations for chronic obstructive pulmonary disease exacerbations: the validity of the Clinical COPD Questionnaire. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014 , 14, 283-7	2.2	10
85	Outcome measures for palliative oxygen therapy: relevance and practical utility. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014 , 14, 417-23	2.2	
84	Bedoradrine for treating asthma and chronic obstructive pulmonary disease. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 1149-56	5.9	2
83	Epratuzumab for systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1045-7	5.4	3

82	Fresh from the designation pipeline: orphan drugs recently designated in the EU (March-April 2014). <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 957-960	1.1	
81	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (September -November 2013). <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 311-315	1.1	2
80	Fresh from the designation pipeline: orphan drugs recently designated in the European Union. <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 249-253	1.1	1
79	Hospitalizations for chronic obstructive pulmonary disease exacerbations and their impact on disease and subsequent morbidity and mortality. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013 , 13, 187-9	2.2	5
78	MP-376 (Aeroquin) for chronic <i>Pseudomonas aeruginosa</i> infections. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 267-76	5.9	10
77	Evaluation of inhaled tiotropium in asthma, uncontrolled with standard combination therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 967-9	4	4
76	Outpatient palliative care effectiveness: both patients and caregivers can gain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013 , 13, 575-7	2.2	
75	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (March -April 2013). <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 765-768	1.1	
74	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (November 2012 -January 2013). <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 499-505	1.1	3
73	Monoclonal antibodies for asthma and chronic obstructive pulmonary disease. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 257-68	5.4	6
72	Tralokinumab for uncontrolled asthma. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 323-6	5.4	5
71	Discontinued drugs for pulmonary, allergy, gastrointestinal, arthritis (2012). <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 1453-64	5.9	
70	Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 671-3	5.9	12
69	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (June -August 2013). <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 1063-1071	1.1	1
68	Novel amikacin inhaled formulation for the treatment of lower respiratory tract infections. <i>Drugs of Today</i> , 2013 , 49, 683-92	2.5	3
67	Inhaled ciprofloxacin for chronic airways infections caused by <i>Pseudomonas aeruginosa</i> . <i>Expert Review of Anti-Infective Therapy</i> , 2012 , 10, 1439-46	5.5	12
66	Discontinued drugs 2011: pulmonary, allergy, gastrointestinal and arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 1607-18	5.9	8
65	Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?. <i>Multidisciplinary Respiratory Medicine</i> , 2012 , 7, 41	3	13

64	Inhaled colistin for lower respiratory tract infections. <i>Expert Opinion on Drug Delivery</i> , 2012 , 9, 333-42	8	29
63	Targeting PDGF pathway in pulmonary arterial hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16, 1055-63	6.4	30
62	Targeting RhoA/ROCK pathway in pulmonary arterial hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16, 355-63	6.4	46
61	Roflumilast as add-on therapy to conventional inhalers in COPD: a cost-effectiveness analysis. <i>Journal of Comparative Effectiveness Research</i> , 2012 , 1, 315-7	2.1	1
60	Humanistic Outcomes and Quality of Life 2012 , 211-220		
59	Predictors of depression in chronic obstructive pulmonary disease patients. <i>Expert Review of Respiratory Medicine</i> , 2011 , 5, 333-5	3.8	5
58	New therapeutic options in the management of COPD - focus on roflumilast. <i>International Journal of COPD</i> , 2011 , 6, 147-55	3	24
57	Therapeutic approaches in hereditary angioedema. <i>Clinical Reviews in Allergy and Immunology</i> , 2011 , 41, 114-22	12.3	13
56	Health status and chronic obstructive pulmonary disease severity. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011 , 11, 399-401	2.2	
55	Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. <i>N Engl J Med</i> 2010;363(18):1693-703. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 351-3	6.4	29
54	Discontinued drugs 2010: rheumatology, allergy and dermatology, pulmonary. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1175-87	5.9	
53	Targeting the Toll-like receptor 7 pathway in asthma: a potential immunomodulatory approach?. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 667-9	6.4	2
52	Terguride for pulmonary arterial hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 1333-5	6.4	3
51	Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 423-5	5.9	2
50	Inhaled gentamicin in non-cystic fibrosis bronchiectasis: effects of long-term therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1191-4	4	8
49	Inhaled phosphodiesterase type 5 inhibitors for cystic fibrosis: a new therapy for systemic disease?. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 713-5	5.9	1
48	Acclidinium bromide in experimental asthma. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 871-3	5.9	2
47	Tiotropium in the treatment of asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 489-91	4	3

46	Varenicline for smoking cessation intervention in chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2595-7	4	4
45	Targeting the TNF-alpha pathway in sarcoidosis. <i>Expert Opinion on Therapeutic Targets</i> , 2010 , 14, 21-9	6.4	28
44	Effects of inhaled therapy on biomarkers of systemic inflammation in stable chronic obstructive pulmonary disease. <i>Biomarkers</i> , 2010 , 15, 97-103	2.6	13
43	Triple inhaled therapy in stable chronic obstructive pulmonary disease: the earlier, the better? Evaluation of Welte T, Miravittles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. <i>Am J Respir Crit Care Med</i> 2009;180:741-50. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1039-42	4	4
42	Pitrakinra for asthma. <i>Expert Opinion on Biological Therapy</i> , 2010 , 10, 1609-15	5.4	13
41	Tiotropium therapy and mortality risk in COPD patients: the most severe, the most protected? Evaluation of Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. <i>Am J Respir Crit Care Med</i> 2009; 180(10): 248-55. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1120-11	4	2
40	Raxibacumab for inhalational anthrax: an effective specific therapeutic approach?. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 909-11	5.9	6
39	Adherence to inhaled therapy in COPD: effects on survival and exacerbations. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010 , 10, 115-7	2.2	14
38	GM-CSF pathway correction in pulmonary alveolar proteinosis. <i>Expert Opinion on Biological Therapy</i> , 2010 , 10, 1357-65	5.4	11
37	Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010 , 10, 155-62	2.2	5
36	Update on models of pulmonary fibrosis therapy for preclinical drug research. <i>Expert Opinion on Drug Discovery</i> , 2009 , 4, 939-46	6.2	5
35	Daclizumab a novel corticosteroid-sparing therapy for asthma?. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 369-71	5.9	6
34	Targeting platelet-derived growth factor with imatinib in idiopathic pulmonary arterial hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2009 , 13, 381-3	6.4	2
33	Mepolizumab for difficult-to-control asthma with persistent sputum eosinophilia. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 869-71	5.9	9
32	Discontinued drugs 2008: pulmonary and allergy. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1799-805	5.9	1
31	Effects of montelukast-desloratadine combination on early and late asthma responses Davis BE, Illamperuma C, Gauvreau GM, et al. Single-dose desloratadine and montelukast and allergen-induced late airway responses. <i>Eur Respir J</i> 2009;33(6):1302-308. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 2577-9	4	1
30	Fudosteine effects on mucin production. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 105-7	5.9	1
29	Ciclesonide therapy in asthma: a potential effect on small airway inflammation?. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 917-9	4	1

28	Itraconazole for severe asthma with fungal sensitivity. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 1231-3	4	
27	Golimumab for severe asthma. <i>Expert Opinion on Investigational Drugs</i> , 2009 , 18, 1421-3	5.9	8
26	Cytokine antagonists for the treatment of asthma: progress to date. <i>BioDrugs</i> , 2009 , 23, 241-51	7.9	11
25	UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Evaluation of: Tashkin DP, Celli B, Senn S et al.: a 4-year trial of tiotropium in chronic obstructive pulmonary disease. <i>N Engl J Med</i> (2008) 359(15):1543-1554. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 719-22	4	12
24	Long-term bronchodilator inhaled therapy in COPD: the role of tiotropium bromidum. <i>Reviews on Recent Clinical Trials</i> , 2009 , 4, 89-98	1.2	
23	Inhaled corticosteroids in COPD: systemic effects of a local therapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 3271-3	4	3
22	Somatostatin analogs for idiopathic pulmonary fibrosis therapy. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1137-40	5.9	3
21	Bosentan for the treatment of idiopathic pulmonary fibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 611-4	5.9	
20	Targeting the endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan. <i>Expert Opinion on Therapeutic Targets</i> , 2008 , 12, 1077-84	6.4	5
19	PDE5 inhibitors for cystic fibrosis: can they also enhance chloride transport? Evaluation of: Lubamba B, Lecourt H, Lebacq J, et al. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. <i>Am J Respir Crit Care Med</i> 2008;177(5):506-15. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 965-8	5.9	3
18	Anti-TNF-alpha therapies in chronic obstructive pulmonary diseases. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1203-11	5.9	21
17	Discontinued drugs, 2007: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 1651-61	5.9	1
16	Targeting the angiotensin pathway in idiopathic pulmonary fibrosis. <i>Expert Opinion on Therapeutic Targets</i> , 2008 , 12, 1587-90	6.4	9
15	Pharmacotherapy of cough-variant asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 3021-8	4	8
14	Inhaled therapy for stable chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 777-85	4	3
13	Infliximab for the therapy of chronic sarcoidosis, Baughman RP, Drent M, Kavuru M et al.: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. <i>Am. J. Respir. Crit. Care Med.</i> (2006) 174(7):795-802. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 753-6	5.9	6
12	Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. <i>N. Engl. J. Med.</i> (2006) 354(25):2655-2666. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 393-5	5.9	3
11	Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 327-30	5.9	2

10	Histone deacetylase pathway: an evolving therapeutic target in chronic obstructive pulmonary disease. <i>Expert Opinion on Therapeutic Targets</i> , 2006 , 10, 329-32	6.4	2
9	Etanercept for refractory asthma therapy. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 1279-81	5.9	4
8	Daily versus intermittent corticosteroids for the treatment of mild persistent asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1235-8	4	1
7	Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 181-4	5.9	7
6	Sildenafil for pulmonary arterial hypertension: when blue turns into white. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1801-10	4	4
5	Formoterol as a rescue medication for asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 2439-41	4	2
4	Targeting tumour necrosis factor-alpha in corticosteroid-dependent asthma. <i>Expert Opinion on Therapeutic Targets</i> , 2006 , 10, 471-3	6.4	1
3	Pirfenidone for the treatment of idiopathic pulmonary fibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 823-8	5.9	30
2	Sildenafil citrate for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 825-8	4	7
1	Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation. <i>Expert Opinion on Investigational Drugs</i> , 2005 , 14, 1443-7	5.9	5